Anti-endothelial cell antibodies in the sera of hyperprolactinemic women

Abstract

Prolactin (PRL) is closely associated with autoimmune diseases in animal models and humans, and several disease-related autoantibodies were reported in increased titers in patients with hyperprolactinemia (HPRL). We studied the presence of anti-endothelial cell antibodies (AECA) and other autoantibodies in sera of female patients with HPRL. Sera from 25 HPRL patients and 10 healthy female controls were tested for AECA (against both macrovascular and microvascular endothelial cell antigens), anti-dsDNA, and anti-cardiolipin (anti-CL) using ELISA. Sera were considered positive for the autoantibody when the optical density (OD) value was more than 3 s.d. above the mean of the OD in normal controls. Sera from 13 patients were obtained repeatedly during dopaminergic anti-PRL treatment, to relate PRL level or anti-PRL treatment with the autoantibody levels. Elevated micro and/or macrovascular AECA were observed in sera from 19=25 patients (76%). Elevated titers of anti-CL Abs, all b2-GPI-dependent, and low levels of anti-dsDNA antibodies (Abs) were also observed in the HPRL patients. Inhibition studies showed that the affinity purified AECAs bound the endothelial cell (EC) antigens in a dose-dependent manner. Titers of AECA as well as anti-DNA and anti-CL autoantibodies did not correlate with PRL level nor with the use or duration of anti-PRL treatment. None of the HPRL patients presented clinical manifestations of autoimmune disease. We conclude that elevated levels of AECA as well as anti-DNA and anti-CL autoantibodies are frequent in hyperprolactinemia. Our results further support the association of PRL and autoimmunity, and may point to a relationship between AECA-associated diseases and HRPL. The presence of autoantibodies in patients with HPRL might portend an increased risk for future development of autoimmune disease.

Keywords

prolactin autoimmunity anti-endothelial cell antibodies anti-DNA antibodies anti-cardiolipin antibodies

Get full access to this article

View all access options for this article.

References

Buskila D , Sukenik S , Shoenfeld Y . The possible role of prolactin in autoimmunity . Am J Reprod Immunol 1991; 26: 118–123 .

Reber PM . Prolactin and immunomodulation . Am J Med 1993; 95: 637–644 .

Jara LJ et al. Prolactin, immunoregulation and autoimmune diseases . Semin Arthritis Rheum 1991; 20: 273–284 .

Lavalle C . Prolactin—a hormone with immunoregulatory properties that lead to new therapeutic approaches in rheumatic diseases . J Rheumatol 1992; 19: 893–841 .

Walker SE . Prolactin: an immune-stimulating peptide that regulates other immune modulating hormones . Lupus 1993; 2: 67–69 .

Nagi E , Berczi I , Friesen HG . Regulation of immunity in rats by lactogenic and growth hormones . Acta Endocrinol 1981; 102: 351–357 .

Lavelle C et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus . J Rheumatol 1987; 14: 268–272 .

Ferrari C et al. Thyroid autoimmunity in hyperprolactinemic disorders . Acta Endocrinol 1983; 104: 35–41 .

Hender LP , Bynke G . Endogenous iridocyclitis relieved during treatment with bromocriptine . Am J Opthalmol 1985; 100: 618–619 .

10.

Blank M , Palestine A , Nussenblatt R , Shoenfeld Y . Down regulation of autoantibody levels with cyclosporin and bromocriptine in treatment of uveitis . Clin Immunol Immunopathol 1990; 54: 87–97 .

11.

Whyte A , Williams O . Bromocriptine suppresses postpartum exacerbation of collagen-induced arthritis . Arthritis Rheum 1988; 31: 927–928 .

12.

Blank M et al. Bromocriptime immunomodulation of experimental SLE and primary anti-phospholipid syndrome via induction of nonspecific T suppressor cells . Cell Immunol 1995; 162: 114–122 .

13.

Buskila D et al. Autoantibody profile in the sera of women with hyperprolactinemia . J Autoimmunity 1995; 8: 415–424 .

14.

Meroni PL , Khamashata MA , Youinou P , Shoenfeld Y . Conference report, mosaic of anti-endothelial antibodies, review of the first international workshop on anti-endothelial antibodies: clinical and pathological significance . Lupus 1995; 4: 95–99 .

15.

Adler Y et al. Anti-endothelial cell antibodies: a need for standardization . Lupus 1994; 3: 77–84 .

16.

Youinou P , Meroni PL , Khamashta MA , Shoenfeld Y . A need for standardization of anti-endothelial-cell antibody test . Immunol Today 1995; 16: 363–364 .

17.

Rosenbaum J et al. Measurement and characterization of circulating antiendothelial cell IgG in connective tissue diseases. Clin Exp Immunol 1988; 450–456.

18.

Bodolay E et al. Cytotoxic endothelial cell antibodies in mixed connective tissue disease . Immunol Lett 1989; 20: 163–167 .

19.

Del Papa N et al. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells . Clin Immunol Immunopathol 1992; 63: 267–274 .

20.

Ferraro G et al. Anti-endothelial cell antibodies in patients with Wegener ' s granolomatosis and micropolyarteritis . Clin Exp Immunol 1990; 79: 47–53 .

21.

Jaffe EA , Nachman R , Becker CG , Minick CR . Culture of human endothelial cells derived from umbilical veins . J Clin Invest 1973; 52: 2745–2756 .

22.

Damianovich M et al. Pathogenic role of antiendothelial cell antibodies (AECA) in vasculitis: an idiotype experimental model . J Immunol 1996; 156: 4946–4951 .

23.

Liu ZY et al. Characterization of signal transduction pathways in human bone marrow endothelial cells . Blood 1997; 90: 2253–2259 .

24.

Shoenfeld Y , Schwartz RS . Immunologic and genetic factors in autoimmune disease . N Engl J Med 1984; 311: 1019–1021 .

25.

Cines DB , Tomaski A , Tannenbaum S . Immune endothelial cell injury in heparin associated thrombocytopenia . New Engl J Med 1987; 316: 581–589 .

26.

Rappaport VJ , Hirata G , Yap HK , Jordan SC . Anti vascular endothelial cell antibodies in severe pre-eclampsia . Am J Obstet Gynecol 1990; 162: 138–146 .

27.

Tsukada N et al. Autantibodies to each protein fraction extracted from cerebral endothelial cell membrane in the sera of patients with multiple sclerosis . J Neuroimmunol 1989; 24: 41–46 .

28.

Stevens TR et al. Anti-endothelial cell antibodies in inflammatory bowel disease . Dig Dis Sci 1993; 38: 426–432 .

29.

Blann AD , Babbs C , Neuberger JM . Endothelial cell damage in primary biliary cirrhosis: influence of cholestasis and immunological mechanisms . Clin Exp Immuno 1992; 90: 88–92 .

30.

Wangel AG et al. Anti-endothelial cell antibodies in insulin dependnet diabetes mellitus . Clin Exp Immunol 1992; 88: 410–413 .

31.

Ferrara N , Clapp C , Weinder R . The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells . Endocrinology 1991; 129: 896–900 .

32.

Clapp C , Weiner R . A specific, high affinity, saturable binding site for the 16-KD fragment of prolactin on capillary endothelial cells . Endocrinology 1992; 130: 1380–1386 .

33.

Wu H , Devi R , Malarkey WB . Expression and localization of prolactin messenger RNA in the human immune system . Endocrinology 1996; 137: 349–353 .

34.

Zimering MB et al. Circulating fibroblast growth factor-like autoantibodies in two patients with multiple endocrine neoplasia type 1 and prolactinoma . J Clin Endocrinol Metab 1994; 79: 1546–1552 .

35.

Lahat V , Miller A , Shtiller R , Touby E . Differential effects of prolactin upon activation and differentiation of human B lymphocytes . J Neuroimmunol 1993; 47: 35–40 .

36.

Gutierrez MA et al. Prolactin-induced immunoglobulin and autoanti-body production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals . Int Arch Allergy Immuno 1996; 109: 229–235 .

37.

Ishibashi M , Yomaji T . Immunological abnormalities with hyperprolactinemia . Endor Soc. 71st Annu Meet 1989, p 407–407 .